Pacer Advisors Inc. Acquires 142,376 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Pacer Advisors Inc. lifted its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 8.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,876,466 shares of the company’s stock after buying an additional 142,376 shares during the period. Pacer Advisors Inc.’s holdings in Protagonist Therapeutics were worth $72,432,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. Nisa Investment Advisors LLC raised its holdings in Protagonist Therapeutics by 10.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company’s stock worth $121,000 after acquiring an additional 295 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Protagonist Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,130 shares of the company’s stock valued at $95,000 after buying an additional 379 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Protagonist Therapeutics by 749.2% in the third quarter. GAMMA Investing LLC now owns 552 shares of the company’s stock valued at $25,000 after buying an additional 487 shares in the last quarter. KBC Group NV increased its holdings in Protagonist Therapeutics by 54.4% during the fourth quarter. KBC Group NV now owns 2,093 shares of the company’s stock worth $81,000 after buying an additional 737 shares during the last quarter. Finally, Exchange Traded Concepts LLC bought a new stake in Protagonist Therapeutics during the third quarter worth $43,000. 98.63% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, insider Arturo Md Molina sold 1,906 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $40.98, for a total value of $78,107.88. Following the sale, the insider now owns 46,444 shares in the company, valued at $1,903,275.12. This trade represents a 3.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Dinesh V. Ph D. Patel sold 78,520 shares of the company’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $46.96, for a total transaction of $3,687,299.20. Following the transaction, the chief executive officer now owns 435,208 shares of the company’s stock, valued at $20,437,367.68. This trade represents a 15.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 209,863 shares of company stock worth $9,689,847 over the last three months. Corporate insiders own 5.40% of the company’s stock.

Protagonist Therapeutics Stock Performance

NASDAQ:PTGX opened at $37.69 on Monday. Protagonist Therapeutics, Inc. has a fifty-two week low of $24.21 and a fifty-two week high of $48.89. The company has a market cap of $2.25 billion, a price-to-earnings ratio of 14.17 and a beta of 2.23. The stock has a fifty day moving average price of $40.00 and a 200-day moving average price of $41.78.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. The firm had revenue of $4.68 million for the quarter, compared to the consensus estimate of $4.50 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. Research analysts predict that Protagonist Therapeutics, Inc. will post 2.28 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Wedbush restated an “outperform” rating and set a $58.00 price objective on shares of Protagonist Therapeutics in a research note on Tuesday, November 19th. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Protagonist Therapeutics in a report on Tuesday, December 10th. BMO Capital Markets began coverage on shares of Protagonist Therapeutics in a report on Friday, December 6th. They issued an “outperform” rating and a $62.00 price objective on the stock. StockNews.com cut shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th. Finally, The Goldman Sachs Group began coverage on Protagonist Therapeutics in a report on Friday, December 6th. They set a “neutral” rating and a $47.00 price objective for the company. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $53.78.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.